

RNS Number : 7524J
EKF Diagnostics Holdings PLC
10 August 2012

**EKF Diagnostics Holdings plc
("EKF" or the "Company" or the "Group")**

HemoCue settlement agreement

EKF Diagnostics Holdings plc (AIM: EKF), a worldwide manufacturer of in-vitro diagnostic devices, announces that subsidiaries of EKF have entered into a Settlement Agreement with HemoCue AB and HemoCue Inc ("HemoCue") in relation to patent-related litigation in Germany and the US.

As a result of the Settlement Agreement all claims are mutually settled and finally resolved. Background information on the patent dispute is contained in the Company's Admission Document dated 15 June 2010.

The effect of this is that EKF's original design cuvette will continue to be sold in all countries other than China, Switzerland, Germany, Denmark, Spain, Finland, Great Britain, Italy, Japan, The Netherlands, Sweden, the United States and South Africa.

EKF's new (symmetrical) design cuvette (U.S. Patent No. 8,110,160; EU Patent No. 2 024 089; German Patent No. 10 2006 025 477; Chinese Patent No. ZL 200780013023.4), whose new design ensures that blood can be collected at any angle without air bubbles collecting in the optical window thus reducing waste, will continue to be sold in all countries world-wide.

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines, CEO

Tel: 029 2071 0570
Mob: 07740 084 452
Mob: 07788 420 859

Canaccord Genuity Limited
Jamie Adams / Mark Dickenson / Lucy Tilley

Tel: 020 7523 8000

Walbrook PR Limited
Paul McManus

Tel: 020 7933 8780
Mob: 07980 541 893 or
paul.mcmanus@walbrookpr.com

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of

building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

For more information please visit the website: www.ekfdiagnostics.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCGGUGARUPPUAU admin HemoCue settlement agreement 20288162 A Fri, 08/10/2012 - 07:00
Company Announcement - General EKF